Pfizer (PFE) Assets Average (2009 - 2026)

Pfizer (PFE) has reported Assets Average for 18 consecutive years, with $204.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 1.21% year-over-year to $204.6 billion in Q2 2026; TTM through Jun 2026 was $204.6 billion, a 1.21% decrease from a year earlier, with the FY2025 full-year figure at $210.8 billion, down 2.61% from the prior year.
• Assets Average was $204.6 billion for Q2 2026 at Pfizer, down from $208.1 billion in the prior quarter.
• Over five years, Assets Average peaked at $224.0 billion in Q1 2024 and troughed at $118.2 billion in Q3 2022.
• A 5-year average of $189.1 billion and a median of $207.3 billion in 2025 frame the typical range for Assets Average.
• Across the five-year window, Assets Average plunged 33.92% in 2022 and soared 65.65% in 2024, its largest moves.
• Over 5 years, Assets Average stood at $119.2 billion in 2022, then gained by 13.21% to $134.9 billion in 2023, then soared by 60.42% to $216.4 billion in 2024, then retreated by 3.63% to $208.6 billion in 2025, then fell by 1.92% to $204.6 billion in 2026.
• The last three Assets Average figures came in at $204.6 billion (Q2 2026), $208.1 billion (Q1 2026), and $208.6 billion (Q4 2025), per Business Quant data.